<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936115</url>
  </required_header>
  <id_info>
    <org_study_id>Osiris Protocol 351</org_study_id>
    <nct_id>NCT02936115</nct_id>
  </id_info>
  <brief_title>TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers</brief_title>
  <official_title>A Multicenter, Randomized, Single-Blind Study Comparing the Clinical Outcomes of TruSkin® and an Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osiris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osiris Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical outcomes of TruSkin® and an Active
      Comparator in patients with chronic diabetic foot ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Osiris decision
  </why_stopped>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients that achieve a 50% or greater reduction in wound size by 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieve complete closure of the index wound by 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients that achieve a 50% or greater reduction in wound size by 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initial wound closure</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of product applications</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with worsening of index wound defined by ≥ 50% increase in wound size</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>TruSkin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryopreserved skin allograft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wound Cover</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator for Diabetic Foot Ulcers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TruSkin®</intervention_name>
    <arm_group_label>TruSkin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Wound Cover</intervention_name>
    <arm_group_label>Wound Cover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18 years and 80 years of age inclusive, as of the date of screening

          2. Confirmed diagnosis of Type 1 or Type 2 Diabetes

          3. An Index Ulcer that is chronic (defined as present for &gt; 4 weeks, but not present for
             more than 52 weeks at the Screening Visit)

          4. Index Ulcer is located below the malleolus

          5. The Index Ulcer is a Diabetic Foot Ulcer (DFU) greater than 3 cm2, inclusive, at the
             Screening Visit

          6. The longest length and longest width measurements for the Index Ulcer are no less than
             1 cm each at the Screening Visit

          7. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of
             exposed muscle, tendon, bone, or joint capsule

          8. Wound is free of necrotic debris

          9. Patient has adequate circulation to the foot as documented by ABI or TBI

        Exclusion Criteria:

          1. Index Ulcer is of non-diabetic pathophysiology

          2. Gangrene is present on any part of the affected foot

          3. Index Ulcer is over a Charcot deformity

          4. Patient is currently receiving dialysis or planning to go on dialysis

          5. Patient has a glycated hemoglobin A1c (HbA1c) level of &gt;12%

          6. Chronic oral steroid use &gt;7.5 mg daily for longer than 3 months at the time of
             screening

          7. Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the
             time of screening

          8. Requiring intravenous (IV) antibiotics to treat the index wound infection at the time
             of screening

          9. Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration

         10. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune
             Deficiency Syndrome (AIDS)

         11. Current evidence of cellulitis, or other evidence of infection including fever or pus
             drainage from the wound site

         12. Current evidence of osteomyelitis or history of osteomyelitis within 30 days of
             screening

         13. Patient has active malignancy other than non-melanoma skin cancer

         14. Patient's Index Ulcer has decreased by ≥ 20% during 1-week screening period

         15. Patient's random blood sugar is &gt; 450 mg/dl at screening

         16. Patient is unable to properly off-load the index wound as a part of standard of care

         17. Patient has untreated alcohol or substance abuse at the time of screening

         18. Pregnant women and women who are breastfeeding

         19. Patient is currently enrolled or participated in another investigational device, drug,
             or biological trial within 30 days of screening

         20. Patient has had within the last 30 days, or is currently undergoing, or is planning
             for wound treatments with growth factors, living skin, dermal substitutes or other
             advanced biological therapies

         21. Patient is an employee, or an immediate family member of an employee, of the sponsor
             company or site research staff conducting the study

         22. Patients who have already been randomized in Protocol 351 at any center may not be
             considered for screening or for re-entry into the trial at any center, even after the
             End of Study Visit

         23. Patients with a history of poor compliance, or an unwillingness or inability to adhere
             to the requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Florida</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Illinois</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Michigan</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Texas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

